Epigenetic Maintenance Strategies after Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is an aggressive hematological malignancy with a 5-year survival rate of 29.5% (1). In recent years, an increased understanding of AML molecular abnormalities has led to the development of targeted therapies for some of the characterized mutations, providing patients with more treatment options (2). Many mutations however still lack defined interventions. The interest in immunotherapeutic mechanisms therefore remains high, particularly in the context of hematopoietic stem cell transplantation (HSCT).
Source: Experimental Hematology - Category: Hematology Authors: Tags: Review Source Type: research